Answers are grounded in this paper and cite their sources.
This review highlights luspatercept’s efficacy in reducing anemia in beta-thalassemia and myelodysplastic syndromes, suggesting a new treatment approach.
Ineffective erythropoiesis (IE) is a hallmark of several hematologic disorders, including β-thalassemia and myelodysplastic syndromes (MDS), leading to chronic anemia and transfusion dependence. IE is often driven by disrupted late-stage erythroid maturation, mediated by overactivation of the Smad2/3 signaling pathway within the transforming growth factor-β (TGF-β) superfamily. This review summarizes current evidence on the mechanism of action and clinical efficacy of luspatercept, a novel activin receptor ligand trap that enhances erythroid maturation by inhibiting Smad2/3 signaling. A literature search was conducted using PubMed through February 2025, focusing on clinical trials and mechanistic studies of luspatercept in β-thalassemia and MDS. In β-thalassemia, luspatercept significantly reduced transfusion burden in phase I–III trials. The pivotal BELIEVE study demonstrated that ≥33% transfusion reduction was achieved in a significantly higher proportion of patients receiving luspatercept compared to placebo. In low-risk MDS (LR-MDS), phase II PACE-MDS and phase III COMMANDS trials showed that luspatercept induced erythroid response (HI-E) and transfusion independence (RBC-TI) in a substantial proportion of patients. COMMANDS further revealed that luspatercept outperformed epoetin alfa in achieving ≥12-week RBC-TI and ≥1.5 g/dL hemoglobin increase, regardless of SF3B1 mutation status or baseline erythropoietin levels. Luspatercept presents a promising treatment strategy for IE in β-thalassemia and LR-MDS. Its ability to promote erythropoiesis, reduce transfusion needs, and maintain a favorable safety profile supports its potential as a new standard of care. Ongoing research will help define its role across broader patient populations.
No takes yet. Share an insight, caveat, or question.
Domoń et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: